- Home
- AVIR vs QUAD Comparison
AVIR vs QUAD Comparison
Compare AVIR & QUAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- QUAD
- Stock Information
- Founded
- AVIR 2012
- QUAD 1971
- Country
- AVIR United States
- QUAD United States
- Employees
- AVIR N/A
- QUAD N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- QUAD Publishing
- Sector
- AVIR Health Care
- QUAD Consumer Discretionary
- Exchange
- AVIR Nasdaq
- QUAD Nasdaq
- Market Cap
- AVIR 273.7M
- QUAD 261.9M
- IPO Year
- AVIR 2020
- QUAD 2010
- Fundamental
- Price
- AVIR $2.55
- QUAD $5.72
- Analyst Decision
- AVIR Hold
- QUAD Strong Buy
- Analyst Count
- AVIR 1
- QUAD 2
- Target Price
- AVIR $6.00
- QUAD $9.45
- AVG Volume (30 Days)
- AVIR 532.5K
- QUAD 362.0K
- Earning Date
- AVIR 05-12-2025
- QUAD 04-29-2025
- Dividend Yield
- AVIR N/A
- QUAD 5.22%
- EPS Growth
- AVIR N/A
- QUAD N/A
- EPS
- AVIR N/A
- QUAD N/A
- Revenue
- AVIR N/A
- QUAD $2,646,800,000.00
- Revenue This Year
- AVIR N/A
- QUAD N/A
- Revenue Next Year
- AVIR N/A
- QUAD N/A
- P/E Ratio
- AVIR N/A
- QUAD N/A
- Revenue Growth
- AVIR N/A
- QUAD N/A
- 52 Week Low
- AVIR $2.60
- QUAD $4.06
- 52 Week High
- AVIR $4.15
- QUAD $9.13
- Technical
- Relative Strength Index (RSI)
- AVIR 37.12
- QUAD 56.83
- Support Level
- AVIR $2.66
- QUAD $4.50
- Resistance Level
- AVIR $3.01
- QUAD $6.12
- Average True Range (ATR)
- AVIR 0.15
- QUAD 0.32
- MACD
- AVIR -0.03
- QUAD 0.10
- Stochastic Oscillator
- AVIR 7.02
- QUAD 75.31
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About QUAD Quad Graphics Inc
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..